Patent settlements for Pfizer/Teva and Mylan/Eisai

18 December 2013

US pharma behemoth Pfizer (NYSE: PFE) says it has settled its long-standing litigation against a US subsidiary of Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) relating to the patent covering the use of erectile dysfunction drug Viagra (sildenafil), which expires in April 2020 (including pediatric exclusivity).

As a result of the settlement, or pay-for-delay deal, Teva will be allowed to launch a generic version of Viagra in the USA on December 11, 2017, or earlier under certain circumstances. In 2012, Viagra recorded sales of $1.14 billion in the USA, and more than $2 billion globally. In Europe, the ED drug started to face generic completion, including a Teva copy.

Teva will pay Pfizer an undisclosed royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential. Teva has received tentative approval from the US Food and Drug Administration for its copy of Viagra.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK